Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Dao Thi Kim Oanh | - |
dc.contributor.author | Hoang Van Hai | - |
dc.contributor.author | Park, Sang Ho | - |
dc.contributor.author | Kim, Hyun-Jung | - |
dc.contributor.author | Han, Byung-Woo | - |
dc.contributor.author | Kim, Hyung-Sook | - |
dc.contributor.author | Hong, Jin-Tae | - |
dc.contributor.author | Han, Sang-Bae | - |
dc.contributor.author | Van Thi My Hue | - |
dc.contributor.author | Nguyen-Hai Nam | - |
dc.date.available | 2019-05-29T09:38:13Z | - |
dc.date.issued | 2011-12 | - |
dc.identifier.issn | 0960-894X | - |
dc.identifier.issn | 1464-3405 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/21035 | - |
dc.description.abstract | Data from clinical studies indicate that inhibitors of Class I and Class II histone deacetylase (HDAC) enzymes show great promise for the treatment of cancer. Zolinza (SAHA, Zolinza) was recently approved by the FDA for the treatment of the cutaneous manifestations of cutaneous T-cell lymphoma. As a part of our ongoing effort to identify novel small molecules to target these important enzymes, we have prepared two series of benzothiazole-containing analogues of SAHA. It was found that several compounds with 6C-bridge linking benzothiazole moiety and hydroxamic functional groups showed good inhibition against HDAC3 and 4 at as low as 1 mu g/ml and exhibited potent cytotoxicity against five cancer cell lines with average IC50 values of as low as 0.81 mu g/ml, almost equipotent to SAHA. (C) 2011 Published by Elsevier Ltd. | - |
dc.format.extent | 4 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | - |
dc.title | Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.bmcl.2011.07.124 | - |
dc.identifier.bibliographicCitation | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, v.21, no.24, pp 7509 - 7512 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000297150600054 | - |
dc.identifier.scopusid | 2-s2.0-81255135685 | - |
dc.citation.endPage | 7512 | - |
dc.citation.number | 24 | - |
dc.citation.startPage | 7509 | - |
dc.citation.title | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | - |
dc.citation.volume | 21 | - |
dc.type.docType | Article | - |
dc.publisher.location | 영국 | - |
dc.subject.keywordAuthor | Histone deacetylase (HDAC) inhibitors | - |
dc.subject.keywordAuthor | Benzothiazole | - |
dc.subject.keywordAuthor | Heterocycle | - |
dc.subject.keywordPlus | HDAC INHIBITORS | - |
dc.subject.keywordPlus | UPDATE | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Organic | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.